Docetaxel liposomes for lung targeted delivery: development and evaluation

References

• Adhikari BR, Dummer J, Gordon KC, Das SC. 2022. An expert opinion on respiratory delivery of high dose powders for lung infections. Expert Opin Drug Deliv. 19(7):795–813. doi: 10.1080/17425247.2022.2089111.
   PubMed Web of Science ®Google Scholar
• Alavi M, Karimi N, Safaei M. 2017. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull. 7(1):3–9. doi: 10.15171/apb.2017.002.
   PubMed Web of Science ®Google Scholar
• Antimisiaris SG, Marazioti A, Kannavou M, Natsaridis E, Gkartziou F, Kogkos G, Mourtas S. 2021. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev. 174:53–86. doi: 10.1016/j.addr.2021.01.019.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Yamamoto Ramos M, Mota-Vega B, Carmona A, Peralta Álvarez MP, et al. 2020. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial. JAMA Oncol. 6(6):856–864. doi: 10.1001/jamaoncol.2020.0409.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, et al. 2021. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 39(7):723–733. doi: 10.1200/JCO.20.01605.
   PubMed Web of Science ®Google Scholar
• Bourquin J, Milosevic A, Hauser D, Lehner R, Blank F, Petri-Fink A, Rothen-Rutishauser B. 2018. Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials. Adv Mater. 30(19):e1704307.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. 2015. Liposomes as nanomedical devices. Int J Nanomed. 10:975–999. doi: 10.2147/IJN.S68861.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang L-W, Huang J-J, Song F-J, Zhang L-P, Qian Z-M, Trevathan E, Mao H-J, Han B, Vaughn M, et al. 2016. Long-term exposure to urban air pollution and lung cancer mortality: a 12-year cohort study in Northern China. Sci Total Environ. 571:855–861. doi: 10.1016/j.scitotenv.2016.07.064.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Gonda I, Chan H-K. 2013. Liposomal formulations for inhalation. Ther Deliv. 4(8):1047–1072. doi: 10.4155/tde.13.71.
   PubMedGoogle Scholar
• Colombo C, Monhemius AJ, Plant JA. 2008. Platinum, palladium and rhodium release from vehicle exhaust catalysts and road dust exposed to simulated lung fluids. Ecotoxicol Environ Saf. 71(3):722–730. doi: 10.1016/j.ecoenv.2007.11.011.
   PubMed Web of Science ®Google Scholar
• Demetzos C. 2008. Differential scanning calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability. J Liposome Res. 18(3):159–173. doi: 10.1080/08982100802310261.
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Mainelis G, Taratula O, Minko T. 2014. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med. 11(1):44–55.
   PubMedGoogle Scholar
• Guo Y, Bera H, Shi C, Zhang L, Cun D, Yang M. 2021. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm Sin B. 11(8):2565–2584. doi: 10.1016/j.apsb.2021.05.015.
   PubMed Web of Science ®Google Scholar
• He Y, Zhang W, Xiao Q, Fan L, Huang D, Chen W, He W. 2022. Liposomes and liposome-like nanoparticles: from anti-fungal infection to the COVID-19 pandemic treatment. Asian J Pharm Sci. 17(6):817–837. doi: 10.1016/j.ajps.2022.11.002.
   PubMed Web of Science ®Google Scholar
• König D, Savic Prince S, Rothschild SI. 2021. Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel). 13(4):804. doi: 10.3390/cancers13040804.
   PubMed Web of Science ®Google Scholar
• Kuzmov A, Minko T. 2015. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 219:500–518. doi: 10.1016/j.jconrel.2015.07.024.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. 2003. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 56(6):588–599. doi: 10.1046/j.1365-2125.2003.01892.x.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang K, Wu D, Ren L, Chu X, Qin C, Han X, Hang T, Xu Y, Yang L, et al. 2021. Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19. Asian J Pharm Sci. 16(6):772–783. doi: 10.1016/j.ajps.2021.09.002.
   PubMed Web of Science ®Google Scholar
• Li M, Du C, Guo N, Teng Y, Meng X, Sun H, Li S, Yu P, Galons H. 2019. Composition design and medical application of liposomes. Eur J Med Chem. 164:640–653. doi: 10.1016/j.ejmech.2019.01.007.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhan S, Liu Q, Su H, Dai X, Wang H, Beng H, Tan W. 2018. Preparation of a sustained-release nebulized aerosol of R-terbutaline hydrochloride liposome and evaluation of its anti-asthmatic effects via pulmonary delivery in Guinea pigs. AAPS PharmSciTech. 19(1):232–241. doi: 10.1208/s12249-017-0816-z.
   PubMed Web of Science ®Google Scholar
• Liu C, Shi J, Dai Q, Yin X, Zhang X, Zheng A. 2015. In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. Drug Dev Ind Pharm. 41(2):272–278. doi: 10.3109/03639045.2013.858740.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang X, Xue J, Chai J, Qin L, Guan J, Zhang X, Mao S. 2022. Exploring the intrinsic micro-/nanoparticle size on their in vivo fate after lung delivery. J Control Release. 347:435–448. doi: 10.1016/j.jconrel.2022.05.006.
   PubMed Web of Science ®Google Scholar
• Lyu D, Chen S, Guo W. 2018. Liposome crosslinked polyacrylamide/DNA hydrogel: a smart controlled-release system for small molecular payloads. Small. 14(15):e1704039. doi: 10.1002/smll.201704039.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhuang H, Zhuang Z, Lu Y, Xia R, Gan L, Wu Y. 2018. Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting. Artif Cells Nanomed Biotechnol. 46(8):1864–1871.
   PubMed Web of Science ®Google Scholar
• Mathur P, Sharma S, Rawal S, Patel B, Patel MM. 2020. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. J Liposome Res. 30(2):182–196. doi: 10.1080/08982104.2019.1614055.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, et al. 2022. Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial. J Clin Oncol. 40(7):719–728. doi: 10.1200/JCO.21.01455.
   PubMed Web of Science ®Google Scholar
• Nagaraju C, Vaidya G, Jain AS, Nair AP, Chandrappa S, Srinivasa C, Suresh KP, Patil SS, Shivananda B, Kollur SP, et al. 2022. Overall survival prediction of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis. Oman Med J. 37(5):e419. doi: 10.5001/omj.2022.86.
   PubMedGoogle Scholar
• Pan L, Zhang S, Gu K, Zhang N. 2018. Preparation of astaxanthin-loaded liposomes: characterization, storage stability and antioxidant activity. CyTA – J Food. 16(1):607–618. doi: 10.1080/19476337.2018.1437080.
   Web of Science ®Google Scholar
• Pelfrêne A, Cave MR, Wragg J, Douay F. 2017. In vitro investigations of human bioaccessibility from reference materials using simulated lung fluids. Int J Environ Res Public Health. 14(2):112.
   PubMed Web of Science ®Google Scholar
• Pirker R. 2020. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr Opin Oncol. 32(1):63–67. doi: 10.1097/CCO.0000000000000592.
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Lilenbaum RC. 2010. Small cell lung cancer: past, present, and future. Curr Oncol Rep. 12(5):327–334. doi: 10.1007/s11912-010-0120-5.
   PubMed Web of Science ®Google Scholar
• Sainaga Jyothi VGS, Bulusu R, Venkata Krishna Rao B, Pranothi M, Banda S, Kumar Bolla P, Kommineni N. 2022. Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update. Int J Pharm. 624:122022. doi: 10.1016/j.ijpharm.2022.122022.
   PubMedGoogle Scholar
• Sawant SS, Patil SM, Shukla SK, Kulkarni NS, Gupta V, Kunda NK. 2022. Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation. Drug Deliv Transl Res. 12(10):2474–2487. doi: 10.1007/s13346-021-01088-0.
   PubMed Web of Science ®Google Scholar
• Schabath MB, Cote ML. 2019. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 28(10):1563–1579. doi: 10.1158/1055-9965.EPI-19-0221.
   PubMed Web of Science ®Google Scholar
• Smola M, Vandamme T, Sokolowski A. 2008. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomed. 3(1):1–19. doi: 10.2147/IJN.S1045.
   PubMed Web of Science ®Google Scholar
• Son Y-J, McConville JT. 2009. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm. 382(1–2):15–22. doi: 10.1016/j.ijpharm.2009.07.034.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 2010. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. (197):3–53. doi: 10.1007/978-3-642-00477-3_1.
   PubMedGoogle Scholar
• Van Rooijen N, Kors N, Ende M, Dijkstra C. 1990. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res. 260(2):215–222. doi: 10.1007/BF00318625.
   PubMed Web of Science ®Google Scholar
• Veldhuizen R, Nag K, Orgeig S, Possmayer F. 1998. The role of lipids in pulmonary surfactant. Biochim Biophys Acta. 1408(2–3):90–108. doi: 10.1016/s0925-4439(98)00061-1.
   PubMed Web of Science ®Google Scholar
• Wallin M, Tagami T, Chen L, Yang M, Chan H-K. 2018. Pulmonary drug delivery to older people. Adv Drug Deliv Rev. 135:50–61. doi: 10.1016/j.addr.2017.11.010.
   PubMed Web of Science ®Google Scholar
• Wang L, Li R, Che K, Liu Z, Xiang S, Li M, Yu Y. 2017. Enhanced antitumor effect on intrapulmonary tumors of docetaxel lung-targeted liposomes in a rabbit model of VX2 orthotopic lung cancer. Sci Rep. 7(1):10069. doi: 10.1038/s41598-017-10530-8.
   PubMedGoogle Scholar
• Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, Karamanos N, Zarogoulidis K. 2012. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomed. 7:1551–1572. doi: 10.2147/IJN.S29997.
   PubMed Web of Science ®Google Scholar
• Zhang E, Xing R, Liu S, Li P. 2019. Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv. 16(3):301–312. doi: 10.1080/17425247.2019.1583644.
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y. 2018. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B. 8(3):440–448. doi: 10.1016/j.apsb.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu P, Qin H, Zhang Y, Sun X, Song X, Liu J, Peng H, Liu Y, Nwafor EO, et al. 2021. Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: rationale and therapeutic potential. Biomed Pharmacother. 133:111072. doi: 10.1016/j.biopha.2020.111072.
   PubMed Web of Science ®Google Scholar
• Zhao J, Su J, Qin L, Zhang X, Mao S. 2020. Exploring the influence of inhaled liposome membrane fluidity on its interaction with pulmonary physiological barriers. Biomater Sci. 8(23):6786–6797. doi: 10.1039/d0bm01529f.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei Y, Li W, Liu Y, Wang Y, Zhong X, Yu Y. 2011. Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. J Drug Target. 19(3):171–178. doi: 10.3109/10611861003801859.
   PubMed Web of Science ®Google Scholar